Purpose | This immunoassay kit allows for the in vitro quantitative determination of human Kidney injury molecule 1,Kim-1 concentrations in urine and other biological fluids. |
Sample Type | Urine, Biological Fluids |
Analytical Method | Quantitative |
Detection Method | Colorimetric |
Specificity | This assay recognizes recombinant and natural human Kim-1. |
Cross-Reactivity (Details) | No significant cross-reactivity or interference was observed. |
Sensitivity | 0.039ng/ml |
Characteristics | Homo sapiens,Human,Hepatitis A virus cellular receptor 1,HAVcr-1,Kidney injury molecule 1,KIM-1,T-cell immunoglobulin and mucin domain-containing protein 1,TIMD-1,T-cell membrane protein 1,TIM-1,TIM, |
Components |
Reagent (Quantity):
|
Material not included | Microplate reader. Pipettes and pipette tips. EP tube Deionized or distilled water. |
Alternative Name | HAVCR1 (HAVCR1 ELISA Kit Abstract) |
Background | Kidney injury molecule-1 (KIM-1) is a type 1 transmembrane protein that is not detectable in normal kidney tissue but is expressed at high levels in rodent kidneys with dedifferentiated proximal tubule epithelial cells after ischemic or toxic injury. |
Sample Volume | 100 μL |
Plate | Pre-coated |
Protocol | The microtiter plate provided in this kit has been pre-coated with an antibody specific to Kim-1. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for Kim-1 and Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a TMB substrate solution is added to each well. Only those wells that contain Kim-1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Kim-1 in the samples is then determined by comparing the O.D. of the samples to the standard curve. |
Reagent Preparation |
Bring all reagents to room temperature before use. Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Dilute 30 mL of Wash Buffer Concentrate into deionized or distilled water to prepare 750 mL of Wash Buffer. Standard - Reconstitute the Standard with 1.0 mL of Sample Diluent. This reconstitution produces a stock solution. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making serial dilutions (Making serial dilution in the wells directly is not permitted). The undiluted standard serves as the high standard. The Sample Diluent serves as the zero standard (0 ng/ml). |
Sample Collection | Urine - Aseptically collect the first urine of the day (mid-stream), voided directly into a sterile container. Centrifuge to remove particulate matter, assay immediately or aliquot and store at ≤ -20C. Avoid repeated freeze-thaw cycles. Other biological fluids - Remove particulates by centrifugation and assay immediately or aliquot and store samples at -20 C or -80 C . Avoid repeated freeze-thaw cycles. Note: Urine to be used within 7 days may be stored at 2-8 C , otherwise samples must stored at -20 C ( ≤ 1 months) or -80 C ( ≤ 2 months) to avoid loss of bioactivity and contamination. Avoid freeze-thaw cycles. When performing the assay slowly bring samples to room temperature. |
Assay Procedure |
Allow all reagents to reach room temperature (Please do not dissolve the reagents at 37 °C directly.). All the reagents should be mixed thoroughly by gently swirling before pipetting. Avoid foaming. Keep appropriate numbers of strips for 1 experiment and remove extra strips from microtiter plate. Removed strips should be resealed and stored at 4 °C until the kits expiry date. Prepare all reagents, working standards and samples as directed in the previous sections. Please predict the concentration before assaying. If values for these are not within the range of the standard curve, users must determine the optimal sample dilutions for their particular experiments. |
Calculation of Results |
Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density. Create a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the x-axis against the concentration on the y-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the SAA concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. It is recommended to use some related software to do this calculation, such as curve expert 13.0. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor. |
Restrictions | For Research Use only |
Handling Advice |
1. The kit should not be used beyond the expiration date on the kit label. 2. Do not mix or substitute reagents with those from other lots or sources. 3. If samples generate values higher than the highest standard, further dilute the samples and repeat the assay. Any variation in standard diluent, operator, pipetting technique, washing technique,incubation time or temperature, and kit age can cause variation in binding. 4. This assay is designed to eliminate interference by soluble receptors, ligands, binding proteins, and other factors present in biological samples. Until all factors have been tested in the Immunoassay, the possibility of interference cannot be excluded. |
Storage | 4 °C/-20 °C |
Storage Comment | The Assay Plate, Standard, Detection Reagent A and Detection Reagent B should be stored at -20°C upon being received. After receiving the kit , Substrate should be always stored at 4°C. |
Product cited in: |
Sohotnik, Nativ, Abbasi, Awad, Frajewicki, Bishara, Sukhotnik, Armaly, Aronson, Heyman, Nativ, Abassi: "Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1." in: American journal of physiology. Renal physiology, Vol. 304, Issue 8, pp. F1099-104, 2013 (PubMed).
Abassi, Shalabi, Sohotnik, Nativ, Awad, Bishara, Frajewicki, Sukhotnik, Abbasi, Nativ: "Urinary NGAL and KIM-1: biomarkers for assessment of acute ischemic kidney injury following nephron sparing surgery." in: The Journal of urology, Vol. 189, Issue 4, pp. 1559-66, 2013 (PubMed). |
Background publications |
Wasilewska, Taranta-Janusz, D?bek, Zoch-Zwierz, Kuroczycka-Saniutycz: "KIM-1 and NGAL: new markers of obstructive nephropathy." in: Pediatric nephrology (Berlin, Germany), Vol. 26, Issue 4, pp. 579-86, 2011 (PubMed).
|